Benmelstobart - Apollomics/Chia Tai Tianqing Pharmaceutical Group
Alternative Names: Anti-PD-L1 monoclonal antibody - Apollomics/Chia Tai Tianqing Pharmaceutical Group; APL 502; CBT-502; PD-L1 antibody - Apollomics/Chia Tai Tianqing Pharmaceutical Group; TQ-B2450Latest Information Update: 28 Jul 2024
At a glance
- Originator Apollomics; Crown Bioscience
- Developer Apollomics; Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Small cell lung cancer
- Preregistration Endometrial cancer
- Phase III Biliary cancer; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Squamous cell cancer
- Phase II/III Adenocarcinoma; Gastric cancer
- Phase II Diffuse large B cell lymphoma; Gynaecological cancer; Hepatitis B; Hodgkin's disease; Liver cancer; Nasopharyngeal cancer; Uterine cancer
- Phase I/II Acral lentiginous melanoma; Cholangiocarcinoma
- Phase I Solid tumours
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Liver-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV, Injection)
- 04 Jul 2024 Chia Tai Tianqing Pharmaceutical Group plans a phase III trial in Small cell lung cancer (Combination therapy) in China (IV) in September 2024 (NCT06469879)
- 31 May 2024 Efficacy and adverse events data from phase-II trial in Biliary cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)